Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: Initial results of RTOG 9802

Journal of Clinical Oncology

Volumn 30, Issue 25, 2012, Pages 3065-3070

  Shaw, Edward G ^a   Wang, Meihua ^b   Coons, Stephen W ^c   Brachman, David G ^d   Buckner, Jan C ^e   Stelzer, Keith J ^f   Barger, Geoffrey R ^g   Brown, Paul D ^e   Gilbert, Mark R ^h   Mehta, Minesh P ⁱ  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b RADIATION THERAPY ONCOLOGY GROUP   (United States)

^c BARROW NEUROLOGICAL INSTITUTE   (United States)

^d Arizona Oncology Services   (United States)

^e MAYO CLINIC   (United States)

^f Celilo Cancer Center   (United States)

^g WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁱ NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOMUSTINE; PROCARBAZINE; VINCRISTINE;

ADULT; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVOR; CONTROLLED STUDY; GLIOMA; HUMAN; LOG RANK TEST; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROBABILITY; PROGRESSION FREE SURVIVAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; TUMOR BIOPSY; WILCOXON SIGNED RANKS TEST; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY, ADJUVANT; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; GLIOMA; HUMANS; KAPLAN-MEIER ESTIMATE; LOMUSTINE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; PROCARBAZINE; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; SUPRATENTORIAL NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME; VINCRISTINE; YOUNG ADULT;

EID: 84865785710     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.35.8598     Document Type: Article

References (24)

1. Kleihues P, Burger PC, Scheithauer BW: Histological Typing of Tumours of the Central Nervous System (ed 2). Berlin, Germany, Springer, 1993
2. Central Brain Tumor Registry of the United States (CBTRUS): Statistical Report: Primary Brain Tumors in the United States, 1998-2002. Hinsdale, IL, CBRTUS, 2006. http://www.cbtrus.org/reports/2005-2006/2006report.pdf
3. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2006. CA Cancer J Clin 56:106-130, 2006
4. Brown PD, Shaw EG: Low-grade gliomas, in Gunderson LL, Tepper JE (eds): Clinical Radiation Oncology (ed 2). Philadelphia, PA, Churchill-Livingstone, 2006, pp 493-514
5. van den Bent MJ, Afra D, de Witte O, et al: Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: The EORTC 22845 randomised trial. Lancet 366:985-990, 2005
6. Karim AB, Maat B, Hatlevoll R, et al: A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer Study (EORTC) Study 22844. Int J Radiat Oncol Biol Phys 36:549-556, 1996
7. Shaw E, Arusell R, Scheithauer B, et al: A prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: Initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group Study. J Clin Oncol 20:2267-2276, 2002
8. Eyre HJ, Crowley JJ, Townsend JJ, et al: A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas. A Southwest Oncology Group study. J Neurosurg 78:909-914, 1993
9. Brada M, Viviers L, Abson C, et al: Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol 14:1715-1721, 2003
10. Kesari S, Schiff D, Drappatz J, et al: Phase II study of protracted daily temozolomide for low-grade gliomas in adults. Clin Cancer Res 15:330-337, 2009
11. Buckner JC, Gesme D Jr, O'Fallon JR, et al: Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: Efficacy and associations with chromosomal abnormalities. J Clin Oncol 21:251-255, 2003
12. Shaw EG, Berkey B, Coons SW, et al: Recurrence following neurosurgeon-determined grosstotal resection of adult supratentorial low-grade glioma: Results of a prospective clinical trial. J Neurosurg 109:835-841, 2008
13. Intergroup Radiation Therapy Oncology Group Trial 9402, Cairncross G, Berkey B, et al: Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24:2707-2714, 2006
14. Cancer Therapy Evaluation Program: Common Toxicity Criteria, Version 2.0. Revised March 23, 1998. http://ctep.cancer.gov/protocolDevelopment/electronic- applications/docs/ctcv20-4-30-992.pdf
15. Zelen M: The randomization and stratification of patients to clinical trials. J Chron Dis 27:365-375, 1974
16. Klein J, Moeschberger M: Survival Analysis: Techniques for Censored and Truncated Data. New York, NY, Springer, 2003
17. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
18. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
19. Cox DR: Regression models and life-tables. J R Stat Soc B 34:187-220, 1972
20. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996, 2005
21. Quinn JA, Reardon DA, Friedman AH, et al: Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol 21:646-651, 2003
22. Pace A, Vidiri A, Galiè E, et al: Temozolomide chemotherapy for progressive low-grade glioma: Clinical benefits and radiological response. Ann Oncol 14:1722-1726, 2003
23. Tosoni A, Franceschi E, Ermani M, et al: Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas. J Neurooncol 89:179-185, 2008
24. Jenkins RB, Blair H, Ballman KV, et al: A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 66:9852-9861, 2006